...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Presentation at AACR Meeting April 10-15
Reply New Message
Back To Forum List View
Icon president Zenith Presentation at AACR Meeting April 10-15
4
BearDownAZ
Apr 09, 2021 02:43PM
Re: Zenith Presentation at AACR Meeting April 10-15
3
Toinv
Apr 11, 2021 11:30AM
Re: Zenith Presentation at AACR Meeting April 10-15
3
fuzzyjr
Apr 11, 2021 02:24PM
Re: Zenith Presentation at AACR Meeting April 10-15
4
KayakerBC
Apr 12, 2021 09:09AM
Re: Zenith Presentation at AACR Meeting April 10-15
2
fuzzyjr
Apr 12, 2021 10:03AM
Re: Zenith Presentation at AACR Meeting April 10-15
3
KayakerBC
Apr 12, 2021 10:29AM
Re: Zenith Presentation at AACR Meeting April 10-15
1
fuzzyjr
Apr 12, 2021 10:46AM

Here is Zenith's poster from the AACR meeting this past weekend.

COMBINATION OF ZEN-3694 WITH TALAZOPARIB IS A NOVEL THERAPEUTIC APPROACH IN ER POSITIVE BREAST CANCER RESISTANT TO CDK4/6 INHIBITORS, INDEPENDENT OF BRCA STATUS

https://www.zenithepigenetics.com/upload/media_element/144/60e9d5b4a936/aacr-2021-1129-kharenko.pdf

 

3 Recommendations
Re: Zenith Presentation at AACR Meeting April 10-15
3
KayakerBC
Apr 12, 2021 11:26AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply